According to data released by the Israeli Ministry of Health, adverse events related to vaccination are less frequent in those who receive the booster. Exhaustion is the most common
the hypothesis of offer the entire adult population the third dose of the Covid vaccine. For now in Italy the booster, with mRna vaccines, is reserved, in order of priority, for immunocompromised people, over 80, residents of the Rsa, health personnel, over 60 and frail, after at least six months from the completion of the primary vaccination cycle (first two doses or single doses J&J). Received the booster also Ilaria Capua, director of the UF One Health Center of the University of Florida, who guest at Of Tuesday he said: To the people who will now get vaccinated, know that it feels. I tell you in such a way that afterwards who knows what stories do not come out.
Therefore, even after the third dose, mild complaints are possible. In fact, according to data released on October 1 by the Israeli Ministry of Health, the effects of the recall are significantly lighter than those of the first two injections. The most common general exhaustionfound in 86.6 people per million versus 271.8 and 251.1 per million after the second and first dose, respectively. Pain in the vaccination area it affected 42.7 people per million in the third dose, against 222.9 and 514.3 in the second and first. The data refers to approx 3 million 200 thousand immunizations with the booster (today there have been 3 million and 900 thousand): there were 19 serious disorders and the possible connection with the vaccine is still being evaluated. In the Faq published on the website of the Israeli Ministry of Health reads: Side effects after the third dose have been found in a small percentage of adults aged 60 and over and are consistent with those seen after the first two doses or other vaccines; they generally include pain at the injection site, headache, fever, chills, muscle pain.
Third dose and booster
According to several studies, the effectiveness of vaccines begins to decline between 6 and 9 months after the last injection. But for immunosuppressed individuals, protection fails much sooner. That is why a distinction was made between third dose and booster: the third dose can be done 28 days after the second and aims to complete the vaccination course in people who have not responded effectively. The recall, on the other hand, can be done starting 6 months after the second injection: aims to reactivate the production of antibodies.
95 percent effectiveness
In fact, according to a study published in recent days on the New England Journal of Medicine, the efficacy of the third Pfizer dose of 95.6%, with 5 cases of infection in the vaccinated group, versus 109 infections in the placebo group (2 Pfizer doses, plus the third with placebo). The results of the trial were presented to the Advisory Committee of the American Food and Drug Administration: neutralizing antibodies were found to be high against all variants, including Beta and Delta. In addition, the maximum effectiveness of the third dose is reached after 7 days. One fifth of the study participants were over the age of 65, a category most at risk of severe Covid. The effectiveness numbers are about the contagion: the ability of vaccines to combat deaths and hospitalizations exceeds 90 percent (and close to 100%) in any analysis even with only the two doses of vaccine, but protection against infections weakens after 6 months, especially in the most exposed categories, for which the third dose is useful.
For Moderna, half a dose is enough
Recently the European Medicines Agency (Ema) gave the green light to the administration of the third dose of Modern vaccine (Spikevax) in people aged 18 and over. For the booster (to be done 6-8 months after the second dose) a half dose is sufficient. The available data, says the EMA, indicate that the risks of side effects after the third dose are similar to those seen after the second. Previously, the Agency had already given the green light for the administration of the third dose of the vaccine Pfizer-BioNTech (Comirnaty) 18 years and older, six months after the second dose. In addition, the EMA stressed that a third dose of both vaccines can be administered to people with severe immune system deficiencies starting 28 days after the second.
October 27, 2021 (change October 27, 2021 | 18:10)
© REPRODUCTION RESERVED
#dose #side #effects